Uniferon® launched in the Baltics

August 29, 2012

The pig production industry in Estonia, Latvia, and Lithuania has gained access to Uniferon®, the industry-leading injectable iron supplement.

A recent introduction of the industry-leading injectable iron supplement Uniferon® to pig producers in the Baltics is yet another step into the world for the Danish pharmaceutical company Pharmacosmos. And a stepping stone for the Baltic pig farmers' work towards being more competitive.

Pharmacosmos is acknowledged as a global leader in iron deficiency treatments for both humans and animals, and the company's Uniferon, which is an all-natural injectable iron supplement for newborn piglets, is used by pig farmers throughout the world.

"Pig production in the Baltics is becoming increasingly focused on global best practice and hence also the generally accepted standard of administering iron to newborn piglets to promote optimal growth and general health as well as avoiding detrimental anaemia. Pig producers in the Baltics are thus becoming increasingly demanding and we are glad that we are now able to support their efforts," said Jens Fabricius, Vice President, Marketing & Business Operations at Pharmacosmos.

Uniferon is marketed through Magnum Veterinarija, a dedicated, long-standing veterinarian-focused partner based in Estonia with subsidiaries in Latvia and Lithuania.

About Uniferon

Uniferon is a modern improved iron hydrogenated dextran based on a natural formula, which is approved for global use:

Uniferon is manufactured without the use of any organic solvents or cyanide, thus, avoiding trace residues of these impurities. Pharmacosmos manufactures iron dextran of high quality and unique purity for customers worldwide. Uniferon is the only injectable iron brand for piglets approved in the EU, the US and Asia.

About Pharmacosmos

Headquartered in Denmark, Pharmacosmos is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use.

A research-based company, its ongoing R&D programme focuses on improving the lives of patients with iron deficiency with or without anaemia. More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. This makes it one of the largest global health challenges of our time.

Pharmacosmos has subsidiaries in the Nordics, the UK and the US and its products are marketed in more than 80 countries across the world. Its manufacturing facilities are approved, among others, by the Danish Medicines Agency and the US FDA.